title: Fluticasone furoate and vilanterol for COPD - authors' reply.
authors.affiliation: AB Lung Health Center Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham & Birmingham VA Medical Center, Birmingham, AL 35294, USA. Electronic address: mdransfield99@msn.com.
authors.forename: Mark T
authors.initials: MT
authors.lastname: Dransfield
authors.affiliation: GlaxoSmithKline, London, UK.
authors.forename: Sally
authors.initials: S
authors.lastname: Lettis
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA.
authors.forename: Frank
authors.initials: F
authors.lastname: Barnhart
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA.
authors.forename: Courtney
authors.initials: C
authors.lastname: Crim
authors.affiliation: University of Liverpool, Liverpool, UK.
authors.forename: Peter M A
authors.initials: PM
authors.lastname: Calverley
mesh_terms: D000730:Androstadienes; D001592:Benzyl Alcohols; D002722:Chlorobenzenes; D005260:Female; D006801:Humans; D008297:Male; D011014:Pneumonia; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012137:Respiratory System / Q000187:drug effects*
chemical_list: D000730:Androstadienes; D001592:Benzyl Alcohols; D002722:Chlorobenzenes